ERBB Fusion clinical trials at UC Cancer
1 research study open to eligible people
Showing trials for
Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions
open to eligible people ages 18 years and up
Open-label, Phase 2, single treatment arm, 3 cohorts
at UC Irvine UCSF
Last updated: